Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain development.

Brain health check Cognition Dopaminergic dysregulation Epigenetics Executive function Genetics Reward deficiency syndrome

Journal

INNOSC theranostics & pharmacological sciences
ISSN: 2705-0734
Titre abrégé: INNOSC Theranostics Pharmacol Sci
Pays: Singapore
ID NLM: 9918646272806676

Informations de publication

Date de publication:
30 Apr 2024
Historique:
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 20 5 2024
Statut: ppublish

Résumé

The Carter Center has estimated that the addiction crisis in the United States (US), if continues to worsen at the same rate, may cost the country approximately 16 trillion dollars by 2030. In recent years, the well-being of youth has been compromised by not only the coronavirus disease 2019 pandemic but also the alarming global opioid crisis, particularly in the US. Each year, deadly opioid drugs claim hundreds of thousands of lives, contributing to an ever-rising death toll. In addition, maternal usage of opioids and other drugs during pregnancy could compromise the neurodevelopment of children. A high rate of DNA polymorphic antecedents compounds the occurrence of epigenetic insults involving methylation of specific essential genes related to normal brain function. These genetic antecedent insults affect healthy DNA and mRNA transcription, leading to a loss of proteins required for normal brain development and function in youth. Myelination in the frontal cortex, a process known to extend until the late 20s, delays the development of proficient executive function and decision-making abilities. Understanding this delay in brain development, along with the presence of potential high-risk antecedent polymorphic variants or alleles and generational epigenetics, provides a clear rationale for embracing the Brain Research Commission's suggestion to mimic fitness programs with an adaptable brain health check (BHC). Implementing the BHC within the educational systems in the US and other countries could serve as an effective initiative for proactive therapies aimed at reducing juvenile mental health problems and eventually criminal activities, addiction, and other behaviors associated with reward deficiency syndrome.

Identifiants

pubmed: 38766548
doi: 10.36922/itps.1472
pmc: PMC11100020
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1472

Déclaration de conflit d'intérêts

Conflict of interest KENNETH BLUM is the holder of both USA and foreign patents related to kb220 and gars. Other authors declare no conflicts of interest.

Auteurs

Kenneth Blum (K)

Division of Addiction Research and Education, Center for Sports, Exercise and Global Mental Health, Western University of Health Sciences, Pomona, California, United States of America.
The Kenneth Blum Behavioral and Neurogenetic Institute LLC, Austin, Texas, United States of America.
Faculty of Education and Psychology, Institute of Psychology, Eötvös Loránd University Budapest, Budapest, Hungary.
Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel.
Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, California, United States of America.
Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Purba Medinipur, West Bengal, India.
Division of Personalized Recovery Science, Transplicegen Therapeutics, Llc., Austin, Tx., United of States.
Department of Psychiatry, University of Vermont, Burlington, Vermont, United States of America.
Department of Psychiatry, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America.
Division of Personalized Medicine, Ketamine Clinic of South Florida, Pompano Beach, Florida, United States of America.

Eric R Braverman (ER)

The Kenneth Blum Behavioral and Neurogenetic Institute LLC, Austin, Texas, United States of America.

Mark S Gold (MS)

Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America.

Catherine A Dennen (CA)

Department of Family Medicine, Jefferson Health Northeast, Philadelphia, Pennsylvania, United States of America.

David Baron (D)

Division of Addiction Research and Education, Center for Sports, Exercise and Global Mental Health, Western University of Health Sciences, Pomona, California, United States of America.

Panayotis K Thanos (PK)

Department of Psychology and Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University of Buffalo, Buffalo, New York, United States of America.

Colin Hanna (C)

Department of Psychology and Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, University of Buffalo, Buffalo, New York, United States of America.

Igor Elman (I)

Cambridge Health Alliance, Harvard Medical School, Cambridge, Massachusetts, United States of America.

Marjorie C Gondre-Lewis (MC)

Department of Anatomy, Howard University School of Medicine, Washington, D.C., United States of America.

J Wesson Ashford (JW)

Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, United States of America.

Andrew Newberg (A)

Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania, United States of America.

Margaret A Madigan (MA)

The Kenneth Blum Behavioral and Neurogenetic Institute LLC, Austin, Texas, United States of America.

Nicole Jafari (N)

Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, California, United States of America.
Department of Human Development, California State University at Long Beach, Long Beach, California, United States of America.

Foojan Zeine (F)

Department of Human Development, California State University at Long Beach, Long Beach, California, United States of America.
Awareness Integration Institute, San Clemente, California, United States of America.

Keerthy Sunder (K)

Department of Health Science, California State University at Long Beach, Long Beach, California, United States of America.
Department of Psychiatry, University California, UC Riverside School of Medicine, Riverside, California, United States of America.

John Giordano (J)

Division of Personalized Medicine, Ketamine Clinic of South Florida, Pompano Beach, Florida, United States of America.

Debmayla Barh (D)

Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Purba Medinipur, West Bengal, India.

Ashim Gupta (A)

Future Biologics, Lawrenceville, Georgia, United States of America.

Paul Carney (P)

Division of Pediatric Neurology, University of Missouri Health Care-Columbia, Columbia, Missouri, United States of America.

Abdalla Bowirrat (A)

Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel.

Rajendra D Badgaiyan (RD)

Department of Psychiatry, Mt. Sinai School of Medicine, New York City, New York, United States of America.

Classifications MeSH